Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist (Q44050790)

29 November 2017

title

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist (English)

1 reference

29 November 2017

0 references

Junko Tsukada

1

1 reference

29 November 2017

Atsuo Tahara

2

1 reference

29 November 2017

Yuichi Tomura

3

1 reference

29 November 2017

Koh ichi Wada

4

1 reference

29 November 2017

Toshiyuki Kusayama

5

1 reference

29 November 2017

Noe Ishii

6

1 reference

29 November 2017

Motonori Aoki

7

1 reference

29 November 2017

Takeyuki Yatsu

8

1 reference

29 November 2017

Wataru Uchida

9

1 reference

29 November 2017

Nobuaki Taniguchi

10

1 reference

29 November 2017

Akihiro Tanaka

11

1 reference

29 November 2017

publication date

1 June 2002

1 reference

European Journal of Pharmacology

29 November 2017

language of work or name

English

0 references

published in

1 reference

29 November 2017

volume

446

1 reference

29 November 2017

issue

1-3

1 reference

29 November 2017

page(s)

129-138

1 reference

Role of vasopressin in abnormal water excretion in cirrhotic patients

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Molecular cloning of the receptor for human antidiuretic hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Renin, aldosterone and arginine vasopressin in patients with liver cirrhosis: the influence of ascites retransfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Attenuation of Genetic Hypertension After Short-term Vasopressin V1A Receptor Antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Cloning and characterization of the human V3 pituitary vasopressin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation to adenylate cyclase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Characterization of specific receptors for vasopressin in the pituitary gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Plasma atrial natriuretic hormone levels in patients with the syndrome of inappropriate antidiuretic hormone secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Molecular cloning and expression of a rat V1a arginine vasopressin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Identification of functional oxytocin receptors in lactating rat mammary gland in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

The vasopressin-sensitive adenylate cyclase in collecting tubules and in thick ascending limb of Henle's loop of human and canine kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Effect of YM087, a Potent Nonpeptide Vasopressin Antagonist, on Vasopressin-Induced Hyperplasia and Hypertrophy of Cultured Vascular Smooth-Muscle Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Characterization of human platelet vasopressin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Effects of vasopressin on human memory functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Upregulation of aquaporin-2 water channel expression in chronic heart failure rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901813-7

10.1016/S0014-2999(02)01813-7

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference